Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review

Journal of Steroid Biochemistry and Molecular Biology

Volumn 168, Issue , 2017, Pages 19-25

  Patel, Seema ^a  

^a SAN DIEGO STATE UNIVERSITY   (United States)

Author keywords

Aromatase; Aromatase inhibitor; Breast cancer; Endocrine disruption; Estrogen; Inflammation

Indexed keywords

ANASTROZOLE; ANDROGEN; AROMATASE; AROMATASE INHIBITOR; DANAZOL; ESTROGEN; EXEMESTANE; GESTODENE; LETROZOLE; CYP19A1 PROTEIN, HUMAN; PESTICIDE;

ALZHEIMER DISEASE; ANDROGEN METABOLISM; AROMATASE DEFICIENCY; BREAST CANCER; BREAST HYPERTROPHY; ENDOMETRIOSIS; EPIPHYSIS; GYNECOMASTIA; HOMEOSTASIS; HUMAN; HYPOGONADISM; HYPOPHYSIS TUMOR; LIVER CANCER; LUNG CANCER; NONHUMAN; OBESITY; OSTEOPOROSIS; OVARY CANCER; OVARY POLYCYSTIC DISEASE; PREMATURE LABOR; PROSTATE CANCER; REVIEW; SCHIZOPHRENIA; SHORT STATURE; STOMACH CANCER; TRANSGENDER; BLOOD; BREAST TUMOR; CHEMISTRY; DRUG EFFECTS; ENDOCRINE SYSTEM; FEMALE; GENETICS; MALE; OVARY TUMOR; PHYSIOLOGY; PREGNANCY; PROSTATE TUMOR; SIGNAL TRANSDUCTION;

ANDROGENS; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENDOCRINE SYSTEM; ENDOMETRIOSIS; ESTROGENS; FEMALE; HOMEOSTASIS; HUMANS; MALE; OBESITY; OSTEOPOROSIS; OVARIAN NEOPLASMS; PESTICIDES; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSGENDER PERSONS;

EID: 85011019571     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2017.01.009     Document Type: Review

References (112)

1. [1] Vicente M da, G.H., Smith, K.M., Syntheses and functionalizations of porphyrin macrocycles. Curr. Org. Synth. 11 (2014), 3–28.
2. [2] Demura, M., Martin, R.M., Shozu, M., et al. Regional rearrangements in chromosome 15q21 cause formation of cryptic promoters for the CYP19 (aromatase) gene. Hum. Mol. Genet. 16 (2007), 2529–2541, 10.1093/hmg/ddm145.
3. [3] Izawa, M., Inoue, M., Osaki, M., et al. Cytochrome P450 aromatase gene (CYP19) expression in gastric cancer. Gastric Cancer 11 (2008), 103–110, 10.1007/s10120-008-0463-x.
4. [4] Blakemore, J., Naftolin, F., Aromatase: contributions to physiology and disease in women and men. Physiology (Bethesda) 31 (2016), 258–269, 10.1152/physiol.00054.2015.
5. [5] Simpson, E.R., Clyne, C., Rubin, G., et al. Aromatase-a brief overview. Annu. Rev. Physiol. 64 (2002), 93–127, 10.1146/annurev.physiol.64.081601.142703.
6. [6] Piriu, G., Torac, E., Gaman, L.E., et al. Clozapine and risperidone influence on cortisol and estradiol levels in male patients with schizophrenia. J. Med. Life. 8 (2015), 548–551.
7. [7] Levy, L.L., Emer, J.J., Female pattern alopecia: current perspectives. Int. J. Womens Health 5 (2013), 541–556, 10.2147/IJWH.S49337.
8. [8] Pazaiti, A., Fentiman, I.S., Basal phenotype breast cancer: implications for treatment and prognosis. Womens Health (Lond Engl) 7 (2011), 181–202, 10.2217/whe.11.5.
9. [9] Darbre, P.D., Underarm antiperspirants/deodorants and breast cancer. Breast Cancer Res., 11(Suppl. (3)), 2009, S5, 10.1186/bcr2424.
10. [10] Pletzer, B.A., Kerschbaum, H.H., 50 years of hormonal contraception-time to find out, what it does to our brain. Front. Neurosci., 8(256), 2014, 10.3389/fnins.2014.00256.
11. [11] Tung, N., Wang, Y., Collins, L.C., et al. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res., 12, 2010, R12, 10.1186/bcr2478.
12. [12] Fabian, C.J., The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. Int. J. Clin. Pract. 61 (2007), 2051–2063, 10.1111/j.1742-1241.2007.01587.x.
13. [13] Le Ray, I., Dell'Aniello, S., Bonnetain, F., et al. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res. Treat. 135 (2012), 603–609, 10.1007/s10549-012-2198-y.
14. [14] Choi, H.J., Lui, A., Ogony, J., et al. Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death. Breast Cancer Res., 17, 2015, 6, 10.1186/s13058-014-0506-7.
15. [15] Castro, B., Sánchez, P., Torres, J.M., et al. Bisphenol an exposure during adulthood alters expression of aromatase and 5α-Reductase isozymes in rat prostate. PLoS One, 8, 2013, e55905, 10.1371/journal.pone.0055905.
16. [16] Nelles, J.L., Hu, W.-Y., Prins, G.S., Estrogen action and prostate cancer. Expert Rev. Endocrinol. Metab. 6 (2011), 437–451, 10.1586/eem.11.20.
17. [17] Sirmans, S.M., Pate, K.A., Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin. Epidemiol. 6 (2013), 1–13, 10.2147/CLEP.S37559.
18. [18] Bates, G.W., Legro, R.S., Longterm management of polycystic ovarian syndrome (PCOS). Mol. Cell. Endocrinol. 373 (2013), 91–97, 10.1016/j.mce.2012.10.029.
19. [19] Madnani, N., Khan, K., Chauhan, P., Parmar G polycystic ovarian syndrome. Indian J. Dermatol. Venereol. Leprol. 79 (2013), 310–321, 10.4103/0378-6323.110759.
20. [20] Teede, H., Deeks, A., Moran, L., et al. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med., 8, 2010, 41, 10.1186/1741-7015-8-41.
21. [21] Naderpoor, N., Shorakae, S., de Courten, B., et al. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum. Reprod. Update 21 (2015), 560–574, 10.1093/humupd/dmv025.
22. [22] Franik, S., Kremer, J.A.M., Nelen, W.L.D.M., Farquhar, C., Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database Syst. Rev., 2014, 10.1002/14651858.cd010287.pub2 CD010287.
23. [23] Ho, S.-M., Estrogen, progesterone and epithelial ovarian cancer. Reprod. Biol. Endocrinol., 1, 2003, 73, 10.1186/1477-7827-1-73.
24. [24] Wei, J.-J., William, J., Bulun, S., Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects. Int. J. Gynecol. Pathol. 30 (2011), 553–568, 10.1097/PGP.0b013e31821f4b85.
25. [25] Mehedintu, C., Plotogea, M.N., Ionescu, S., Antonovici, M., Endometriosis still a challenge. J. Med. Life. 7 (2014), 349–357.
26. [26] Bloski, T., Pierson, R., Endometriosis and chronic pelvic pain: unraveling the mystery behind this complex condition. Nurs. Womens Health 12 (2008), 382–395, 10.1111/j.1751-486X.2008.00362.x.
27. [27] Macer, M.L., Taylor, H.S., Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility. Obstet. Gynecol. Clin. North Am. 39 (2012), 535–549, 10.1016/j.ogc.2012.10.002.
28. [28] Bulun, S.E., Monsivais, D., Kakinuma, T., et al. Molecular biology of endometriosis: from aromatase to genomic abnormalities. Semin. Reprod. Med. 33 (2015), 220–224, 10.1055/s-0035-1554053.
29. [29] Beavis, A.L., Smith, A.J.B., Fader, A.N., Lifestyle changes and the risk of developing endometrial and ovarian cancers: opportunities for prevention and management. Int. J. Womens Health 8 (2016), 151–167, 10.2147/IJWH.S88367.
30. [30] Pavone, M.E., Bulun, S.E., Aromatase inhibitors for the treatment of endometriosis. Fertil. Steril. 98 (2012), 1370–1379, 10.1016/j.fertnstert.2012.08.053.
31. [31] Cocciadiferro, L., Miceli, V., Granata, O.M., Carruba, G., Merlin, the product of NF2 gene, is associated with aromatase expression and estrogen formation in human liver tissues and liver cancer cells. J. Steroid Biochem. Mol. Biol., 2016, 10.1016/j.jsbmb.2016.05.023.
32. [32] Verma, M.K., Miki, Y., Abe, K., et al. Co-expression of estrogen receptor beta and aromatase in Japanese lung cancer patients: gender-dependent clinical outcome. Life Sci. 91 (2012), 800–808, 10.1016/j.lfs.2012.08.029.
33. [33] Selek, A., Cetinarslan, B., Gurbuz, Y., et al. Aromatase enzyme expression in acromegaly and its possible relationship with disease prognosis. Endocrine 49 (2015), 250–257, 10.1007/s12020-014-0445-1.
34. [34] Gonzales, P.H., Mezzomo, L.C., Ferreira, N.P., et al. Aromatase P450 expression in human pituitary adenomas. Neuropathology 35 (2015), 16–23, 10.1111/neup.12145.
35. [35] Rambhatla, A., Mills, J.N., Rajfer, J., The role of estrogen modulators in male hypogonadism and infertility. Rev. Urol. 18 (2016), 66–72, 10.3909/riu0711.
36. [36] Faglia, G., Arosio, M., Porretti, S., Delayed closure of epiphyseal cartilages induced by the aromatase inhibitor anastrozole. Would it help short children grow up?. J. Endocrinol. Invest. 23 (2000), 721–723, 10.1007/bf03345059.
37. [37] de Ronde, W., de Jong, F.H., Aromatase inhibitors in men: effects and therapeutic options. Reprod. Biol. Endocrinol., 9, 2011, 93, 10.1186/1477-7827-9-93.
38. [38] Singh, S.K., Aromatase inhibitors in male sex. Indian J. Endocrinol. Metab. 17 (2013), S259–61, 10.4103/2230-8210.119594.
39. [39] Geffner, M.E., Aromatase inhibitors to augment height: continued caution and study required. J. Clin. Res. Pediatr. Endocrinol. 1 (2009), 256–261, 10.4274/jcrpe.v1i6.256.
40. [40] Diaz-Thomas, A., Shulman, D., Use of aromatase inhibitors in children and adolescents: what's new?. Curr. Opin. Pediatr. 22 (2010), 501–507, 10.1097/MOP.0b013e32833ab888.
41. [41] Crosnoe-Shipley, L.E., Elkelany, O.O., Rahnema, C.D., Kim, E.D., Treatment of hypogonadotropic male hypogonadism: case-based scenarios. World J. Nephrol. 4 (2015), 245–253, 10.5527/wjn.v4.i2.245.
42. [42] Cuhaci, N., Polat, S.B., Evranos, B., et al. Gynecomastia: clinical evaluation and management. Indian J. Endocrinol. Metab. 18 (2014), 150–158, 10.4103/2230-8210.129104.
43. [43] Metwalley, K.A., Farghaly, H.S., Aromatase excess syndrome presenting with prepubertal gynecomastia in an Egyptian child with type 1 neurofibromatosis. Indian J. Hum. Genet. 19 (2013), 472–474, 10.4103/0971-6866.124379.
44. [44] Cohen, P.G., Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection. Med. Hypotheses 56 (2001), 702–708, 10.1054/mehy.2000.1169.
45. [45] Rüster, C., Wolf, G., The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases. Semin. Nephrol. 33 (2013), 44–53, 10.1016/j.semnephrol.2012.12.002.
46. [46] Segura, J., Ruilope, L.M., Obesity, essential hypertension and renin-angiotensin system. Public Health Nutr. 10 (2007), 1151–1155, 10.1017/S136898000700064X.
47. [47] Thethi, T., Kamiyama, M., Kobori, H., The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr. Hypertens. Rep. 14 (2012), 160–169, 10.1007/s11906-012-0245-z.
48. [48] Bruno, R.D., Njar, V.C.O., Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg. Med. Chem. 15 (2007), 5047–5060, 10.1016/j.bmc.2007.05.046.
49. [49] Ngun, T.C., Ghahramani, N., Sánchez, F.J., et al. The genetics of sex differences in brain and behavior. Front. Neuroendocrinol. 32 (2011), 227–246, 10.1016/j.yfrne.2010.10.001.
50. [50] Gagliardi, L., Scott, H.S., Feng, J., Torpy, D.J., A case of Aromatase deficiency due to a novel CYP19A1 mutation. BMC Endocr. Disord., 14(16), 2014, 10.1186/1472-6823-14-16.
51. [51] Raisz, L.G., Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest. 115 (2005), 3318–3325, 10.1172/JCI27071.
52. [52] Drake, M.T., Clarke, B.L., Lewiecki, E.M., The pathophysiology and treatment of osteoporosis. Clin. Ther. 37 (2015), 1837–1850, 10.1016/j.clinthera.2015.06.006.
53. [53] Kilbreath, S., Refshauge, K.M., Beith, J., et al. Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: rationale and design of a randomized controlled trial. Contemp. Clin. Trials 32 (2011), 704–709, 10.1016/j.cct.2011.04.012.
54. [54] Baykan, E.K., Erdoğan, M., Özen, S., et al. Aromatase deficiency, a rare syndrome: case report. J. Clin. Res. Pediatr. Endocrinol. 5 (2013), 129–132, 10.4274/Jcrpe.970.
55. [55] Bulun, S.E., Aromatase and estrogen receptor α deficiency. Fertil. Steril. 101 (2014), 323–329, 10.1016/j.fertnstert.2013.12.022.
56. [56] Zhu, W.-J., Cheng, T., Zhu, H., et al. Aromatase deficiency: a novel compound heterozygous mutation identified in a Chinese girl with severe phenotype and obvious maternal virilization. Mol. Cell. Endocrinol. 433 (2016), 66–74, 10.1016/j.mce.2016.05.025.
57. [57] Kolarova, M., García-Sierra, F., Bartos, A., et al. Structure and pathology of tau protein in Alzheimer disease. Int. J. Alzheimers Dis., 2012, 2012, 731526, 10.1155/2012/731526.
58. [58] Wharton, W., Gleason, C.E., Miller, V.M., Asthana, S., Rationale and design of the kronos early estrogen prevention study (KEEPS) and the KEEPS cognitive and affective sub study (KEEPS cog). Brain Res. 1514 (2013), 12–17, 10.1016/j.brainres.2013.04.011.
59. [59] Garcia-Segura, L.M., Wozniak, A., Azcoitia, I., et al. Aromatase expression by astrocytes after brain injury: implications for local estrogen formation in brain repair. Neuroscience 89 (1999), 567–578.
60. [60] Janicki, S.C., Park, N., Cheng, R., et al. Aromatase variants modify risk for Alzheimer's disease in a multiethnic female cohort. Dement. Geriatr. Cogn. Disord. 35 (2013), 340–346, 10.1159/000343074.
61. [61] Gupta, S., Kulhara, P., What is schizophrenia: a neurodevelopmental or neurodegenerative disorder or a combination of both? A critical analysis. Indian J. Psychiatry 52 (2010), 21–27, 10.4103/0019-5545.58891.
62. [62] Kulkarni, J., Gavrilidis, E., Worsley, R., et al. The role of estrogen in the treatment of men with schizophrenia. Int. J. Endocrinol. Metab. 11 (2013), 129–136, 10.5812/ijem.6615.
63. [63] Gogos, A., Sbisa, A.M., Sun, J., et al. A role for estrogen in schizophrenia: clinical and preclinical findings. Int. J. Endocrinol., 2015, 2015, 615356, 10.1155/2015/615356.
64. [64] Xu, R., Mao, B., Li, S., et al. Structure-activity relationships of phthalates in inhibition of human placental 3β-hydroxysteroid dehydrogenase 1 and aromatase. Reprod. Toxicol. 61 (2016), 151–161, 10.1016/j.reprotox.2016.04.004.
65. [65] Kumar, P., Magon, N., Hormones in pregnancy. Niger. Med. J. 53 (2012), 179–183, 10.4103/0300-1652.107549.
66. [66] Kim, J.Y., Han, E.H., Kim, H.G., et al. Bisphenol A-induced aromatase activation is mediated by cyclooxygenase-2 up-regulation in rat testicular Leydig cells. Toxicol. Lett. 193 (2010), 200–208, 10.1016/j.toxlet.2010.01.011.
67. [67] Onat, A., Hergenç, G., Karabulut, A., et al. Serum sex hormone-binding globulin, a determinant of cardiometabolic disorders independent of abdominal obesity and insulin resistance in elderly men and women. Metabolism 56 (2007), 1356–1362, 10.1016/j.metabol.2007.05.020.
68. [68] Hero, M., Aromatase inhibitors in the treatment of short stature. Endocr. Dev. 30 (2016), 130–140, 10.1159/000439338.
69. [69] Miller, C.A., Gindin, Y., Lu, C., et al. Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nat. Commun., 7, 2016, 12498, 10.1038/ncomms12498.
70. [70] Li, R., Cui, J., Shen, Y., Brain sex matters: estrogen in cognition and Alzheimer's disease. Mol. Cell. Endocrinol. 389 (2014), 13–21, 10.1016/j.mce.2013.12.018.
71. [71] Fields, J., Richardson, A., Hopkinson, J., Fenlon, D., Nordic walking as an exercise intervention to reduce pain in women with aromatase inhibitor-associated arthralgia: a feasibility study. J. Pain Symptom Manage. 52 (2016), 548–559, 10.1016/j.jpainsymman.2016.03.010.
72. [72] Mariotti, V., Page, D.B., Davydov, O., et al. Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: an enhanced screening approach incorporating trabecular bone score. J. Bone Oncol., 2016, 10.1016/j.jbo.2016.10.004.
73. [73] Borrie, A.E., Kim, R.B., Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers. Expert Opin. Drug Metab. Toxicol., 2016, 1–8, 10.1080/17425255.2017.1234605.
74. [74] Chen, S., Oh, S.-R., Phung, S., et al. Anti-Aromatase activity of phytochemicals in white button mushrooms (Agaricus bisporus). Cancer Res. 66 (2006), 12026–12034, 10.1158/0008-5472.CAN-06-2206.
75. [75] Kijima, I., Phung, S., Hur, G., et al. Grape seed extract is an aromatase inhibitor and a suppressor of aromatase expression. Cancer Res. 66 (2006), 5960–5967, 10.1158/0008-5472.CAN-06-0053.
76. [76] Endringer, D.C., Guimarães, K.G., Kondratyuk, T.P., et al. Selective inhibition of aromatase by a dihydroisocoumarin from Xyris pterygoblephara. J. Nat. Prod. 71 (2008), 1082–1084, 10.1021/np800098f.
77. [77] Balunas, M.J., Su, B., Brueggemeier, R.W., Kinghorn, A.D., Natural products as aromatase inhibitors. Anticancer Agents Med. Chem. 8 (2008), 646–682.
78. [78] Wang, C., Mäkelä, T., Hase, T., et al. Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J. Steroid Biochem. Mol. Biol. 50 (1994), 205–212.
79. [79] Batra, P., Sharma, A.K., Anti-cancer potential of flavonoids: recent trends and future perspectives. 3 Biotech 3 (2013), 439–459, 10.1007/s13205-013-0117-5.
80. [80] Singh, S., Awasthi, M., Pandey, V.P., Dwivedi, U.N., Plant derived anti-cancerous secondary metabolites as multipronged inhibitor of COX, Topo and aromatase: molecular modeling and dynamics simulation analyses. J. Biomol. Struct. Dyn., 2016, 1–16, 10.1080/07391102.2016.1241720.
81. [81] Chandrareddy, A., Muneyyirci-Delale, O., McFarlane, S.I., Murad, O.M., Adverse effects of phytoestrogens on reproductive health: a report of three cases. Complement. Ther. Clin. Pract. 14 (2008), 132–135, 10.1016/j.ctcp.2008.01.002.
82. [82] Patisaul, H.B., Jefferson, W., The pros and cons of phytoestrogens. Front. Neuroendocrinol. 31 (2010), 400–419, 10.1016/j.yfrne.2010.03.003.
83. [83] Soy, S.V., Soy and phytoestrogens: possible side effects. Ger. Med. Sci., 12, 2014, 10.3205/000203 (Doc18).
84. [84] Vrtačnik, P., Ostanek, B., Mencej-Bedrač, S., Marc, J., The many faces of estrogen signaling. Biochem. Med. 24 (2014), 329–342, 10.11613/BM.2014.035.
85. [85] Majumdar, A., Mangal, N.S., Hyperprolactinemia. J. Hum. Reprod. Sci. 6 (2013), 168–175, 10.4103/0974-1208.121400.
86. [86] La, Torre D., Falorni, A., Pharmacological causes of hyperprolactinemia. Ther. Clin. Risk Manag. 3 (2007), 929–951.
87. [87] Richard, S., Moslemi, S., Sipahutar, H., et al. Differential effects of glyphosate and roundup on human placental cells and aromatase. Environ. Health Perspect. 113 (2005), 716–720, 10.1289/ehp.7728.
88. [88] Zarn, J.A., Brüschweiler, B.J., Schlatter, J.R., Azole fungicides affect mammalian steroidogenesis by inhibiting sterol 14 alpha-demethylase and aromatase. Environ. Health Perspect. 111 (2003), 255–261.
89. [89] Egbuta, C., Lo, J., Ghosh, D., Mechanism of inhibition of estrogen biosynthesis by azole fungicides. Endocrinology 155 (2014), 4622–4628, 10.1210/en.2014-1561.
90. [90] Biegon, A., Alia-Klein, N., Fowler, J.S., Potential contribution of aromatase inhibition to the effects of nicotine and related compounds on the brain. Front. Pharmacol., 3(185), 2012, 10.3389/fphar.2012.00185.
91. [91] Kiyomi, A., Makita, M., Iwase, T., et al. Clinical significance of female-hormones and cytokines in Breast cancer patients complicated with aromatase inhibitor-related osteoarthropathy – efficacy of vitamin e. J. Cancer 6 (2015), 367–376, 10.7150/jca.10695.
92. [92] Veldhuis, J.D., Keenan, D.M., Liu, P.Y., et al. The aging male hypothalamic-pituitary-gonadal axis: pulsatility and feedback. Mol. Cell. Endocrinol. 299 (2009), 14–22, 10.1016/j.mce.2008.09.005.
93. [93] Cohen, P.G., Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection. Med. Hypotheses 56 (2001), 702–708, 10.1054/mehy.2000.1169.
94. [94] Catalano, S., Marsico, S., Giordano, C., et al. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J. Biol. Chem. 278 (2003), 28668–28676, 10.1074/jbc.M301695200.
95. [95] Basu, S., Combe, K., Kwiatkowski, F., et al. Cellular expression of cyclooxygenase, aromatase, adipokines, inflammation and cell proliferation markers in Breast cancer specimen. PLoS One, 10, 2015, e0138443, 10.1371/journal.pone.0138443.
96. [96] Subbaramaiah, K., Morris, P.G., Zhou, X.K., et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed Breast tissue of obese women. Cancer Discov. 2 (2012), 356–365, 10.1158/2159-8290.CD-11-0241.
97. [97] Sirianni, R., Chimento, A., De Luca, A., et al. Inhibition of cyclooxygenase-2 down-regulates aromatase activity and decreases proliferation of Leydig tumor cells. J. Biol. Chem. 284 (2009), 28905–28916, 10.1074/jbc.M109.041020.
98. [98] Fowler, J.M., Ramirez, N., Cohn, D.E., et al. Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis. Am. J. Obstet. Gynecol., 192, 2005, 1262-71-3, 10.1016/j.ajog.2005.01.009.
99. [99] Vona-Davis, L., Rose, D.P., Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr. Relat. Cancer 14 (2007), 189–206, 10.1677/ERC-06-0068.
100. [100] García-Barrado, M.J., Blanco, E.J., Catalano-Iniesta, L., et al. Relevance of pituitary aromatase and estradiol on the maintenance of the population of prolactin-positive cells in male mice. Steroids 111 (2016), 121–126, 10.1016/j.steroids.2016.03.020.
101. [101] Gill-Sharma, M.K., K, M., Prolactin and male fertility: the long and short feedback regulation. Int. J. Endocrinol., 2009(687259), 2009, 10.1155/2009/687259.
102. [102] Pasqualini, J.R., Chetrite, G., The anti-aromatase effect of progesterone and of its natural metabolites 20alpha- and 5alpha-dihydroprogesterone in the MCF-7aro breast cancer cell line. Anticancer Res. 28 (2008), 2129–2133.
103. [103] Hardy, D.B., Janowski, B.A., Chen, C.-C., Mendelson, C.R., Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms. Mol. Endocrinol. 22 (2008), 1812–1824, 10.1210/me.2007-0443.
104. [104] Caglar, A.S., Kapucu, A., Dar, K.A., et al. Localization of the aromatase enzyme expression in the human pituitary gland and its effect on growth hormone, prolactin, and thyroid stimulating hormone axis. Endocrine 49 (2015), 761–768, 10.1007/s12020-015-0537-6.
105. [105] Nelson, L.R., Bulun, S.E., Estrogen production and action. J. Am. Acad. Dermatol. 45 (2001), S116–24.
106. [106] Gillies, G.E., McArthur, S., Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. Pharmacol. Rev. 62 (2010), 155–198, 10.1124/pr.109.002071.
107. [107] Wang, H., Li, R., Hu, Y., The alternative noncoding exons 1 of aromatase (Cyp19) gene modulate gene expression in a posttranscriptional manner. Endocrinology 150 (2009), 3301–3307, 10.1210/en.2008-1812.
108. [108] Abdel-Qadir, H., Amir, E., Fischer, H.D., et al. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer. Eur. J. Cancer 68 (2016), 11–21, 10.1016/j.ejca.2016.08.022.
109. [109] Petkovic, H., Thamchaipenet, A., Zhou, L.H., et al. Disruption of an aromatase/cyclase from the oxytetracycline gene cluster of Streptomyces rimosus results in production of novel polyketides with shorter chain lengths. J. Biol. Chem. 274 (1999), 32829–32834.
110. [110] Lee, M.-Y., Ames, B.D., Tsai, S.-C., Insight into the molecular basis of aromatic polyketide cyclization: crystal structure and in vitro characterization of WhiE-ORFVI. Biochemistry 51 (2012), 3079–3091, 10.1021/bi201705q.
111. [111] Brachmann, A.O., Joyce, S.A., Jenke-Kodama, H., et al. A type II polyketide synthase is responsible for anthraquinone biosynthesis in Photorhabdus luminescens. ChemBioChem 8 (2007), 1721–1728, 10.1002/cbic.200700300.
112. [112] Zahid, H., Simpson, E.R., Brown, K.A., Inflammation, dysregulated metabolism and aromatase in obesity and breast cancer. Curr. Opin. Pharmacol. 31 (2016), 90–96, 10.1016/j.coph.2016.11.003.